DC Vaccine containing WT1/PRAME: Phase I/II started

Medigene began an open-label, Norwegian Phase I/II trial to evaluate its DC Vaccine containing WT1/PRAME for 50 weeks in about 20 AML patients who show complete remission after standard chemotherapy b...